| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0036 | 0.9 |
| mRNA | Merck60 | CTRPv2 | pan-cancer | AAC | -0.0031 | 0.9 |
| mRNA | ML006 | CTRPv2 | pan-cancer | AAC | 0.0039 | 0.9 |
| mRNA | BRD-K63431240 | CTRPv2 | pan-cancer | AAC | -0.0035 | 0.9 |
| mRNA | YL54 | CTRPv2 | pan-cancer | AAC | 0.0039 | 0.9 |
| mRNA | MLN2238 | CTRPv2 | pan-cancer | AAC | -0.0033 | 0.9 |
| mRNA | KU-55933 | GDSC1000 | pan-cancer | AAC | -0.0033 | 0.9 |
| mRNA | GSK4112 | CTRPv2 | pan-cancer | AAC | 0.0035 | 0.9 |
| mRNA | HG-5-113-01 | GDSC1000 | pan-cancer | AAC | -0.0042 | 0.9 |
| mRNA | Bicalutamide | GDSC1000 | pan-cancer | AAC | -0.003 | 0.9 |